About Immune Targeting Systems
Immune Targeting System is a London based vaccine company developing vaccines for mutating viruses. The company's synthetic T cell platform aims to allow to develop vaccines for the prevention and treatment of major life-threatening viral infections of global impact, including pandemic and seasonal influenza.
Missing: Immune Targeting Systems's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Immune Targeting Systems's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Immune Targeting Systems
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Immune Targeting Systems is included in 1 Expert Collection, including Biopharma Tech.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Immune Targeting Systems Patents
Immune Targeting Systems has filed 1 patent.
Immunology, Immune system, Clusters of differentiation, Vaccines, HIV/AIDS
Immunology, Immune system, Clusters of differentiation, Vaccines, HIV/AIDS
Latest Immune Targeting Systems News
Aug 27, 2019
Bill joins Vaccitech after an accomplished 11 years as CEO at Gaithersburg-based Altimmune Inc, a company developing novel immunotherapies and vaccines. He led Altimmune through a significant period of growth including a Series B financing, the acquisition of Immune Targeting Systems - a UK T-cell vaccine company - and taking the company public on NASDAQ through the acquisition of PharmAthene. Bill’s prior experience includes executive and management roles at GenVec (now Intrexon), Biotech Venture Management and Life Technologies Corporation (now ThermoFisher). Dr. Andrew McLean, Vaccitech Board Member, Oxford Science Innovation, said “We’re incredibly excited to welcome Bill Enright to lead Vaccitech to build a world-leading T-cell induction immunotherapy company.” “I am delighted to join Vaccitech during this exciting growth phase, ahead of pivotal Phase II data from its lead influenza program and several other key pipeline inflection points. I have been very impressed by the Company’s management team as well as its innovative T cell induction platform. I am looking forward to working with the team to drive the company through the next phase of its development.” said Bill Enright. Having successfully built Vaccitech to a late clinical stage biopharmaceutical company, in his new role as CSO, Tom Evans MD, will focus more specifically on the science, research and development that underpin Vaccitech’s next generation T-cell induction products. “We believe that Bill’s background and leadership skills are well suited to the Company’s next phase of development and are looking forward to welcoming him to the role. We are extremely grateful to Tom Evans under whose leadership the company has grown rapidly, with over 2000 participants currently in clinical trials. We look forward to Tom’s continuing involvement and excellent scientific leadership as Vaccitech’s CSO." added Robin Wright, Vaccitech Chairman. Caption: Bill Enright Vaccitech is a late-stage T cell immunotherapy company developing non-replicating viral vectors as vaccines to treat and prevent cancer and infectious diseases. The company’s proprietary technology platform, comprising Chimp Adenovirus Oxford (prime) and MVA (boost), is able to create high magnitude CD8+ and CD4+ T cell responses, which can be utilized to clear foreign pathogens and tumours. The Vaccitech prime-boost platform is licenced from the prestigious Jenner Institute for vaccine research at the University of Oxford. This platform has generated a robust pipeline of eight programmes (four of which are funded through partners). Vaccitech currently has a Phase 2b clinical programme for influenza and is poised to enter the clinic with HBV and HPV therapeutics. Vaccitech is also progressing other products funded by partners, including a Phase 2a study in prostate cancer and Phase 1 for MERS. Vaccitech is backed by leading investment institutions, including GV (formerly Google Ventures), Sequoia China and Oxford Sciences Innovation. Contacts
Immune Targeting Systems Frequently Asked Questions (FAQ)
When was Immune Targeting Systems founded?
Immune Targeting Systems was founded in 2003.
Where is Immune Targeting Systems's headquarters?
Immune Targeting Systems's headquarters is located at London Bioscience Innovation, Centre, London.
What is Immune Targeting Systems's latest funding round?
Immune Targeting Systems's latest funding round is Acquired.
How much did Immune Targeting Systems raise?
Immune Targeting Systems raised a total of $28M.
Who are the investors of Immune Targeting Systems?
Investors of Immune Targeting Systems include Altimmune, HealthCap Venture Capital, London Technology Fund, Truffle Capital, Novartis Venture Funds and 3 more.
Who are Immune Targeting Systems's competitors?
Competitors of Immune Targeting Systems include BlueWillow Biologics, ISA Pharmaceuticals, FluGen, Immune Design, Profectus BioSciences and 16 more.
Compare Immune Targeting Systems to Competitors
Developing genetically modified vaccines to protect against common seasonal influenza and emergent pandemic influenza. Formed to commercialize patented vaccine and virus technologies developed at the Mount Sinai School of Medicine, Vivaldi's program represents a approach to flu vaccine development and production and a major advance over flu vaccines available today.
ImmBio is a vaccine company developing vaccine systems. The portfolio addresses areas of high unmet need, where the risk and consequence of infection are severe.
Vaxent has developed a StepNovA vaccine for Group A streptococcus
nnFor more than fifty years, the company have been plotting the route in Allergy medicine. The company have been leading generations of allergists to some of the most discoveries in this science:na vaccine by bronchial route, a vaccine by nasal route, the Methacholine Challenge Test, the Test Dose for foodstuff or additives allergy, and allergens adsorbed on single-use needles.
The focus of Savine Therapeutics is to develop and commercialise vaccines for prevention and treatment of diseases using it's Scrambled Antigen Vaccine (SAVINE) technology. The technology was invented by researchers in the John Curtin School of Medical Research at the Australian National University. Per the company, it enables production of vaccines suitable for a broad range of serious worldwide infectious diseases and cancers. See www.savine.com
adjuvant system relying on the use of anti-CD40 antibodies mode of action may allow the system to be used in combination with other adjuvants and in situations where existing systems don't work Proof of concept achieved in pre-clinical studies Interested in partnering for vaccine development and to source anti CD40
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.